AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A delayed release oral pharmaceutical dosage form comprising a core material coated with a semipermeable membrane, wherein:

the core material comprises an active ingredient selected from the group consisting of omeprazole, an alkaline salt thereof, *S*-omeprazole and an alkaline salt thereof, one or more alkaline additives, one or more swelling agents, and optionally pharmaceutically acceptable excipients;

the membrane consists essentially of a water-insoluble polymer and a modifying agent and is able to disrupt;

and the dosage form is not enteric coated,

wherein the modifying agent and water insoluble polymer are present in a weight ratio of from 90:10 to 50:50.

Claim 2 (cancelled)

Claim 3 (previously presented) The dosage form according to claim 1, wherein the active ingredient is omeprazole.

Claim 4 (previously presented) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of omeprazole having a crystallinity of more than 70% as determined by X-ray powder diffraction.

Claim 5 (previously presented) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of *S*-omeprazole.

Claim 6 (previously presented) The dosage form according to claim 1, wherein the core material comprises a sugar sphere layered with a suspension or solution of the active ingredient, one or more alkaline additives, one or more swelling agents and optionally pharmaceutically acceptable excipients.

Claim 7 (previously presented) The dosage form according to claim 1, wherein the dosage form comprises individual pellets of the core material coated with the semipermeable membrane.

Claim 8 (previously presented) The dosage form according to claim 1, wherein the core material further comprises an osmotic agent.

Claim 9 (previously presented) The dosage form according to claim 1, wherein the alkaline additive gives a pH of not less than 8.5 when measured in a 2% w/w water solution/dispersion with a pH-measuring electrode.

Claim 10 (previously presented) The dosage form according to claim 9, wherein the alkaline additive is selected from the group consisting of disodium hydrogen phosphate, trisodium phosphate, arginine and talc.

Claim 11 (previously presented) The dosage form according to claim 1, wherein the alkaline additive is present in an amount of approximately 5 to 35% by weight of the core material excluding the weight of an optional sugar sphere.

Claim 12 (previously presented) The dosage form according to claim 1, wherein the alkaline additive is present in an amount of 15 to 35% by weight of the core material excluding the weight of an optional sugar sphere.

Claim 13 (previously presented) The dosage form according to claim 1, wherein the swelling agent is selected from the group consisting of crosslinked polyvinyl pyrrolidone, crosslinked sodium carboxymethylcellulose, sodium starch glycolate and low-substituted hydroxypropyl cellulose (L-HPC).

Claim 14 (previously presented) The dosage form according to claim 1, wherein the swelling agent is present in an amount of approximately 20 to 60% by weight of the core material excluding the weight of an optional sugar sphere.

Claim 15 (previously presented) The dosage form according to claim 1, wherein the swelling agent is present in an amount of 30 to 50% by weight of the core material excluding the weight of an optional sugar sphere.

Claim 16 (previously presented) The dosage form according to claim 1, wherein the modifying agent is talc or fumed silica.

Claim 17 (previously presented) The dosage form according to claim 1, wherein the water insoluble polymer is selected from the group consisting of ethylcellulose, cellulose acetate, polyvinyl acetate, and ammonio methacrylate copolymer type A and type B.

Claim 18 (previously presented) The dosage form according to claim 1, wherein the water insoluble polymer is present in an amount of approximately 3-30% by weight of the core material.

Claim 19 (canceled)

Claim 20 (previously presented) A process for the manufacture of a delayed release dosage form as defined in claim 1, comprising forming a core material comprising an active ingredient selected from the group consisting of omeprazole, an alkaline salt thereof, *S*-omeprazole and an alkaline salt thereof, one or more alkaline additives, one or more swelling agents, and optionally pharmaceutically acceptable excipients, and coating the core material with a semipermeable membrane, wherein the dosage form has no enteric coating.

Claim 21 (canceled)

Claim 22 (canceled)

Claim 23 (currently amended) A method for improving inhibition of gastric acid secretion which comprises administering to a patient in need thereof, a delayed release oral pharmaceutical dosage form according to any one of claims 1, **3-18** or 28 [~~3-19~~].

Claim 24 (currently amended) A method for improving the therapeutic effect in the treatment of gastrointestinal disorders associated with excess acid secretion which comprises administering to a patient in need thereof, a delayed release oral pharmaceutical dosage form according to any one of claims 1, **3-18 or 28** [~~3-19~~].

Claim 25 (currently amended) A delayed release oral dosage form according to any one of claims 1, **3-18 or 28** [~~3-19~~] filled in a capsule.

Claim 26 (currently amended) A delayed release oral dosage form according to any one of claims 1, **3-18 or 28** [~~3-19~~] compressed into a multiple unit tablcted dosage form, optionally comprising tablet excipients.

27. (previously presented) The dosage form according to any one of claims 11-13, wherein the core material further comprises an osmotic agent.

28. (new) The dosage form according to claim 1, wherein the modifying agent and water insoluble polymer are present in a weight ratio of from 80:20 to 60:40.